General Information of Drug (ID: DMYPWHD)

Drug Name
NLG919
Synonyms
NLG919; 1402836-58-1; 1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol; NLG 919; CHEMBL3629569; AK166956; 1-Cyclohexyl-2-(5H-imidazo-[5,1-a]isoindol-5-yl)ethanol; alpha-Cyclohexyl-5H-imidazo[5,1-a]isoindole-5-ethanol; 1-Cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethan-1-ol; YTRRAUACYORZLX-UHFFFAOYSA-N; GTPL9019; SCHEMBL13280897; GDC0919; EX-A574; DTXSID20735206; MolPort-035-395-785; HMS3653M05; AOB87373; GDC 0919; NLG919(GDC-0919); 2588AH; RG6078; BDBM50126144; s7111; AKOS025287054; CS-3512; SB16495; ACN-028914; KS-0000062W
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 282.4
Logarithm of the Partition Coefficient (xlogp) 3.5
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 2
Chemical Identifiers
Formula
C18H22N2O
IUPAC Name
1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol
Canonical SMILES
C1CCC(CC1)C(CC2C3=CC=CC=C3C4=CN=CN24)O
InChI
InChI=1S/C18H22N2O/c21-18(13-6-2-1-3-7-13)10-16-14-8-4-5-9-15(14)17-11-19-12-20(16)17/h4-5,8-9,11-13,16,18,21H,1-3,6-7,10H2
InChIKey
YTRRAUACYORZLX-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
66558287
ChEBI ID
CHEMBL3629569
CAS Number
1402836-58-1
TTD ID
D06MHZ
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Immune checkpoint (ICH) TTV8N19 NOUNIPROTAC Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039434)
2 Deal watch: Genentech dives deeper into the next wave of cancer immunotherapies. Nat Rev Drug Discov. 2014 Dec;13(12):879.